ReCode THERAPEUTICS

Powering the future of genetic medicines with precision delivery

nature "Seven technologies to watch in 2022"

FIERCE Biotech FIERCE 15 2022 WINNER

ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ReCode's proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to organs, tissues, and cells for improved efficacy and potency. ReCode is developing therapeutics for genetically defined diseases with no existing treatment options, including primary ciliary dyskinesia and cystic fibrosis.

Pipeline

	Indication	Modality	Target	Delivery	Discovery	Preclinical	Phase 1/2
LUNG	Primary Ciliary Dyskinesia (PCD)	mRNA	DNAI1	Inhaled			
		mRNA	CCDC39/40	Inhaled			
		mRNA	PCD gene 3	Inhaled			
	Cystic Fibrosis (CF)	mRNA	CFTR	Inhaled			
		Gene correction	CFTR	Inhaled			
	Other	mRNA	Undisclosed	Inhaled / IV			
		Gene correction	Undisclosed	Inhaled / IV			
LIVER	Various	Multiple	Undisclosed	IV			
CNS	Various	Multiple	Undisclosed	Intrathecal			

Leadership

An experienced team with substantial genetic medicines, orphan drug and technology development expertise

SHEHNAAZ SULIMAN, M.D., M.B.A., M.Phil
Chief Executive Officer

DAVID LOCKHART, Ph.D.
President & Chief Scientific Officer

JOHN G. MATTHEWS, MBBS, MRCP, Ph.D.
Chief Medical Officer

SORT LNP Platform

ReCode's platform is the foundation for our disease-modifying mRNA and gene correction therapeutics pipeline. The SORT LNPs are used to package and deliver genetic cargo such as mRNA, siRNA and gene correction modalities.

SORT LNP technology offers programmable and precise delivery, enhanced potency, packaging versatility and compatibility with many different routes of administration.

Engineered with distinct and novel lipids and lipid ratios, ReCode's SORT LNP platform powers a library of LNPs that are tuned to reach specific organs and cells.



AMGEN · AyurMaya Capital Management · Bioluminescence Ventures · Coll Ventures · Cystic Fibrosis Foundation · EcoR1 Capital · leaps · MPM · OrbiMed · OSAGE University Partners · Pfizer Ventures · sanofi ventures · Solasta Ventures · VIDA ventures

Menlo Park, CA | Durham, NC
info@recodetx.com
ReCode Therapeutics